tiprankstipranks
Advertisement
Advertisement
Grace Therapeutics price target lowered to $8 from $12 at TD Cowen
PremiumThe FlyGrace Therapeutics price target lowered to $8 from $12 at TD Cowen
1M ago
Grace Therapeutics: Buy Rating Maintained as Addressable CMC Setback Delays but Does Not Derail GTx‑104 Value Thesis
Premium
Ratings
Grace Therapeutics: Buy Rating Maintained as Addressable CMC Setback Delays but Does Not Derail GTx‑104 Value Thesis
1M ago
Grace Therapeutics Receives FDA Complete Response for GTx-104
Premium
Company Announcements
Grace Therapeutics Receives FDA Complete Response for GTx-104
1M ago
Grace Therapeutics reports Q3 EPS (14c) vs (36c) last year
PremiumThe FlyGrace Therapeutics reports Q3 EPS (14c) vs (36c) last year
4M ago
Ten new option listings and two option delistings on January 22nd
Premium
The Fly
Ten new option listings and two option delistings on January 22nd
5M ago
Grace Therapeutics Enhances Executive Severance and Change‑in‑Control Terms
Premium
Company Announcements
Grace Therapeutics Enhances Executive Severance and Change‑in‑Control Terms
5M ago
Grace Therapeutics secures $4M through common warrant exercises
PremiumThe FlyGrace Therapeutics secures $4M through common warrant exercises
8M ago
Grace Therapeutics announces presentation of Phase 3 STRIVE-ON safety trial
Premium
The Fly
Grace Therapeutics announces presentation of Phase 3 STRIVE-ON safety trial
9M ago
Grace Therapeutics Secures New Patent for GTx-104
Premium
Company Announcements
Grace Therapeutics Secures New Patent for GTx-104
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100